Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. Th... Pluristem Therapeutics Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Nevada. Pluristem Therapeutics Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on June 30th. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Pluristem Therapeutics Inc. Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Show more
HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various...
HAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for...
HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based...
The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor Cyrille Cohen, Head of the laboratory of tumor immunology and immunotherapy...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.02 | 0.416666666667 | 4.8 | 4.83 | 4.2 | 10744 | 4.41935922 | CS |
| 4 | -0.0162 | -0.334973739713 | 4.8362 | 5.75 | 4.2 | 29206 | 5.21034818 | CS |
| 12 | -0.9 | -15.7342657343 | 5.72 | 6.18 | 4.2 | 26558 | 5.1385169 | CS |
| 26 | -0.59 | -10.9057301294 | 5.41 | 6.72 | 4.2 | 16609 | 5.2303741 | CS |
| 52 | 0.172 | 3.70051635112 | 4.648 | 8.48 | 3.7728 | 47484 | 5.82033957 | CS |
| 156 | -3.18 | -39.75 | 8 | 11.5784 | 3.4488 | 57787 | 6.39609136 | CS |
| 260 | -3.18 | -39.75 | 8 | 11.5784 | 3.4488 | 57787 | 6.39609136 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
